Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
69.934USD
+0.574+0.83%
Market hours （ET）Quotes delayed by 15 min
13.69BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.83%
5 Days
+3.77%
1 Month
+1.18%
6 Months
-8.62%
Year to Date
-8.57%
1 Year
+57.33%
Key Figures
69.590Open
70.280High
419.89KVolume
LossP/E TTM
123.62P/E Dynamic
--Dividend TTM
0.21%Turnover Ratio
69.360Prev. Close
69.260Low
20.24MTurnover
LossP/E Static
-6.01P/B
0.00%Div Yield TTM
-64.80%ROA
84.94052wk High
0.76Volume Ratio
-535.76MNet Profit
195.71MShares
-3.7466EPS TTM
0.99Beta
--ROE
31.77052wk Low
1.47%Amplitude
94.89%Gross Margin
13.69BMarket Cap
0.82Reward/Risk
2.92%Risk Rate
TradingKey Stock Score of BridgeBio Pharma Inc
Currency: USD Updated: 2026-06-24Key Insights
BridgeBio Pharma Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 104.25.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BridgeBio Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
BridgeBio Pharma Inc Highlights
StrengthsRisks
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 5296.93% year-on-year.
Undervalued
The company’s latest PE is -18.51, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 195.09M shares, decreasing 0.67% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 13.24M shares of this stock.
Analyst Rating
Based on
24
analysts
Buy
Current Rating
104.249
Target Price
+57.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BridgeBio Pharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BridgeBio Pharma Inc Info
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
Ticker SymbolBBIO
CompanyBridgeBio Pharma Inc
CEOKumar (Neil)
Websitehttps://bridgebio.com/
Related Instruments
+1.28%
+2.51%
+1.61%
+2.53%
+2.31%
+1.29%
+1.74%
+0.95%
+0.27%
+0.19%
+1.73%
+1.74%
+2.43%
+0.81%
+1.54%
0.00%
+0.80%
+1.80%
+4.25%
-0.25%Popular Instruments
52641.100
+669.400 (+1.29%)
29460.100
-334.100 (-1.12%)
7406.600
-3.800 (-0.05%)
15763.000
+226.000 (+1.46%)
71558.000
+601.000 (+0.85%)
6279.100
+50.900 (+0.82%)
70.474
+0.715 (+1.02%)
279.370
-13.710 (-4.68%)
194.715
-4.285 (-2.15%)
4019.080
+20.340 (+0.51%)
FAQs
What is the current price of BridgeBio Pharma Inc (BBIO)?
The current price of BridgeBio Pharma Inc (BBIO) is 69.36.
What is the symbol of BridgeBio Pharma Inc?
The ticker symbol of BridgeBio Pharma Inc is BBIO.
What is the 52-week high of BridgeBio Pharma Inc?
The 52-week high of BridgeBio Pharma Inc is 84.94.
What is the 52-week low of BridgeBio Pharma Inc?
The 52-week low of BridgeBio Pharma Inc is 31.77.
What is the market capitalization of BridgeBio Pharma Inc?
The market capitalization of BridgeBio Pharma Inc is 13.58B.
Is BridgeBio Pharma Inc (BBIO) currently rated as Buy, Hold, or Sell?
According to analysts, BridgeBio Pharma Inc (BBIO) has an overall rating of Buy, with a price target of 104.25.
What is the Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO)?
The Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO) is -3.79.
